SCHEMBL606446

SCHEMBL606446

COc1cc2oc(=O)cc(C)c2cc1OC

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.66
ALDH1A1 P00352 9/20 0.66
HPGD P15428 7/20 0.66
HSD17B10 Q99714 7/20 0.66
GAA P10253 4/20 0.66
GLA P06280 2/20 0.66
MAPT P10636 2/20 0.66
HSP90AA1 P07900 1/20 0.66
HSP90AB1 P08238 1/20 0.66
ALPG P10696 1/20 0.66
ALOX15 P16050 1/20 0.66
ALOX12 P18054 1/20 0.66
CASP1 P29466 1/20 0.66
CASP7 P55210 1/20 0.66
SMN1; SMN2 Q16637 1/20 0.66
MCL1 Q07820 4/20 0.58
CYP3A4 P08684 1/20 0.58
THRB P10828 1/20 0.58
AKR1B1 P15121 1/20 0.58
CYP1A2 P05177 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30819091 1.00 KDM4E (0.66) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL8807762 0.86 KDM4E (0.70) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL31282379 0.86 KDM4E (0.70) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL2183416 0.86 KDM4E (0.70) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL9367076 0.85 KDM4E (0.54) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL69332 0.85 MCL1 (0.63) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL8808189 0.84 KDM4E (0.53) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL8809073 0.83 KDM4E (0.49) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL15842381 0.82 KDM4E (0.62) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL4271081 0.81 KDM4E (0.50) KDM4EALDH1A1HPGDHSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110934864-A Application of 4-methyl-6, 7-dimethoxycoumarin in preparing medicine for preventing and treating diabetic nephropathy 佛山科学技术学院 2020-03-31 CN claimed
US-9127092-B2 Method for producing polydienes and polydiene copolymers with reduced cold flow BRIDGESTONE CORPORATION (JP) 2015-09-08 US claimed
US-20140187725-A1 METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW BRIDGESTONE CORPORATION (JP) 2014-07-03 US claimed
US-8410110-B2 9-(piperazinylalkyl) carbazoles as Bax-modulators MERCK SERONO SA (CH) 2013-04-02 US claimed
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2012-02-16 US claimed
US-8053436-B1 9-(piperazinylalkyl) carbazoles as bax-modulators MERCK SERONO SA (CH) 2011-11-08 US claimed
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP claimed
EP-1237887-A1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS Applied Research Systems ARS Holding N.V. (AN) 2002-09-11 EP claimed
WO-2001029028-A1 9- (PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-04-26 WO claimed
US-5663029-A DEVELOPMENT OF LATENT IMAGE, TRANSFERRING TO FORM RECORDING SHEETS, COATING A SUBSTRATE USING POLYMERS XEROX CORPORATION (US) 1997-09-02 US claimed
EP-3674381-B1 ORGANIC OPTICAL MATERIAL JAPAN SCIENCE & TECH AGENCY (JP) 2023-05-10 EP disclosed
CN-113975270-A New application of coumarin 广州康臣药业有限公司 2022-01-28 CN disclosed
CN-113917009-A Construction method and application of bupleurum chinense non-saponin component HPLC fingerprint 山西大学 2022-01-11 CN disclosed
US-20200284946-A1 ORGANIC OPTICAL MATERIAL JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2020-09-10 US disclosed
US-20200284946-A1 ORGANIC OPTICAL MATERIAL JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2020-09-10 US disclosed
WO-2010078333-A2 BENZOXAZOLE-BASED FLUORESCENT METAL ION INDICATORS Life Technologies Corporation (US) 2010-07-08 WO disclosed
US-20100028469-A1 Extracts of Cranberry and Methods of Using Thereof HERBALSCIENCE GROUP, LLC (US) 2010-02-04 US disclosed
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP disclosed
EP-1237887-A1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS Applied Research Systems ARS Holding N.V. (AN) 2002-09-11 EP disclosed
WO-2001029028-A1 9- (PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200284946-A1 ORGANIC OPTICAL MATERIAL SLC43A1, SLCO4C1, SLCO1A2 KDM4E 3282/4885ALDH1A1 693/4885HPGD 4073/4885
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS BCL2, BAX, BAD KDM4E 1555/4885ALDH1A1 2766/4885HPGD 2369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.